_id
69130effccc777a4e85d7dee
Ticker
LIXTW
Name
Lixte Biotechnology Holdings Inc
Exchange
NASDAQ
Address
680 East Colorado Boulevard, Pasadena, CA, United States, 91101
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://lixte.com
Description
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Last Close
0.022
Volume
-
Current Price
0.022
Change
0
Last Updated
2025-12-01T10:16:21.587Z
Image
data:image/webp;base64,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
Ipo Date
2020-11-25T00:00:00.000Z
Market Cap
39486820
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
1801354
Operating Income
-1801354
Interest Expense
457
Pretax Income
-2030765
Net Income
-2030765
Eps
-0.3290715979644137
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
-2030308
Operating Margin
-
Total Other Income Expense Net
-229411
Cash
2887874
Short Term Investments
2454473
Receivables
-
Inventories
-
Total Current Assets
5433676
Property Plant Equipment
-
Total Assets
5433676
Payables
235900
Short Term Debt
-
Long Term Debt
-
Total Liabilities
521422
Equity
4912254
Depreciation
-
Change In Working Capital
49437
Cash From Operations
-926752
Capital Expenditures
2
Cash From Investing
-2637360
Cash From Financing
5564774
Net Change In Cash
2000662
PE
-
PB
0.027638287840978906
ROE
-41.34079793105161
ROA
-37.373685880424226
FCF
-926754
Fcf Percent
-
Piotroski FScore
1
Health Score
42
Deep Value Investing Score
5.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
3
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
7
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
1801354
Quarters > 0 > income Statement > operating Income
-1801354
Quarters > 0 > income Statement > interest Expense
457
Quarters > 0 > income Statement > pretax Income
-2030765
Quarters > 0 > income Statement > net Income
-2030765
Quarters > 0 > income Statement > eps
-0.3290715979644137
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
6171195
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-2030308
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-229411
Quarters > 0 > balance Sheet > cash
2887874
Quarters > 0 > balance Sheet > short Term Investments
2454473
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
5433676
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
5433676
Quarters > 0 > balance Sheet > payables
235900
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
521422
Quarters > 0 > balance Sheet > equity
4912254
Quarters > 0 > cash Flow > net Income
-1980398
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
49437
Quarters > 0 > cash Flow > cash From Operations
-926752
Quarters > 0 > cash Flow > capital Expenditures
2
Quarters > 0 > cash Flow > cash From Investing
-2637360
Quarters > 0 > cash Flow > cash From Financing
5564774
Quarters > 0 > cash Flow > net Change In Cash
2000662
Quarters > 0 > ratios > PE
-0.3290715979644137
Quarters > 0 > ratios > PB
0.027638287840978906
Quarters > 0 > ratios > ROE
-41.34079793105161
Quarters > 0 > ratios > ROA
-37.373685880424226
Quarters > 0 > ratios > FCF
-926754
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
42
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
774809
Quarters > 1 > income Statement > operating Income
-774809
Quarters > 1 > income Statement > interest Expense
1810
Quarters > 1 > income Statement > pretax Income
-775673
Quarters > 1 > income Statement > net Income
-775673
Quarters > 1 > income Statement > eps
-0.28511802650436513
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
2720533
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-773863
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-864
Quarters > 1 > balance Sheet > cash
887212
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
989752
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
1188578
Quarters > 1 > balance Sheet > payables
92149
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
537122
Quarters > 1 > balance Sheet > equity
651456
Quarters > 1 > cash Flow > net Income
-775673
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
20189
Quarters > 1 > cash Flow > cash From Operations
-487485
Quarters > 1 > cash Flow > capital Expenditures
5
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-10000
Quarters > 1 > cash Flow > net Change In Cash
-497485
Quarters > 1 > ratios > PE
-0.28511802650436513
Quarters > 1 > ratios > PB
0.09187378119166913
Quarters > 1 > ratios > ROE
-119.067596276648
Quarters > 1 > ratios > ROA
-65.26058870347592
Quarters > 1 > ratios > FCF
-487490
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
38
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
706940
Quarters > 2 > income Statement > operating Income
-706940
Quarters > 2 > income Statement > interest Expense
3135
Quarters > 2 > income Statement > pretax Income
-709555
Quarters > 2 > income Statement > net Income
-709555
Quarters > 2 > income Statement > eps
-0.28709337155013953
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
2471513
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
520
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-2615
Quarters > 2 > balance Sheet > cash
1384697
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
1514228
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
1514228
Quarters > 2 > balance Sheet > payables
112476
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
355098
Quarters > 2 > balance Sheet > equity
1159130
Quarters > 2 > cash Flow > net Income
-709555
Quarters > 2 > cash Flow > depreciation
706940
Quarters > 2 > cash Flow > change In Working Capital
41334
Quarters > 2 > cash Flow > cash From Operations
-568483
Quarters > 2 > cash Flow > capital Expenditures
3
Quarters > 2 > cash Flow > cash From Investing
914228
Quarters > 2 > cash Flow > cash From Financing
914228
Quarters > 2 > cash Flow > net Change In Cash
345745
Quarters > 2 > ratios > PE
-0.28709337155013953
Quarters > 2 > ratios > PB
0.04690870394174941
Quarters > 2 > ratios > ROE
-61.21444531674618
Quarters > 2 > ratios > ROA
-46.859191614472856
Quarters > 2 > ratios > FCF
-568486
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
42
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
613497
Quarters > 3 > income Statement > operating Income
-613497
Quarters > 3 > income Statement > interest Expense
4432
Quarters > 3 > income Statement > pretax Income
-617694
Quarters > 3 > income Statement > net Income
-617694
Quarters > 3 > income Statement > eps
-0.2746527345486883
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
2249000
Quarters > 3 > income Statement > income Tax Expense
966879
Quarters > 3 > income Statement > EBITDA
-1574000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-4197
Quarters > 3 > balance Sheet > cash
1038952
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
1145503
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
1145503
Quarters > 3 > balance Sheet > payables
83206
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
318284
Quarters > 3 > balance Sheet > equity
827219
Quarters > 3 > cash Flow > net Income
-617694
Quarters > 3 > cash Flow > depreciation
613497
Quarters > 3 > cash Flow > change In Working Capital
-58958
Quarters > 3 > cash Flow > cash From Operations
-598675
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
0
Quarters > 3 > cash Flow > net Change In Cash
-598675
Quarters > 3 > ratios > PE
-0.2746527345486883
Quarters > 3 > ratios > PB
0.05981245595180962
Quarters > 3 > ratios > ROE
-74.6711572147158
Quarters > 3 > ratios > ROA
-53.92338562186219
Quarters > 3 > ratios > FCF
-598675
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
42
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
3572789
Annuals > 0 > income Statement > operating Income
-3572789
Annuals > 0 > income Statement > interest Expense
16821
Annuals > 0 > income Statement > pretax Income
-3585965
Annuals > 0 > income Statement > net Income
-3585965
Annuals > 0 > income Statement > eps
-1.5944708759448645
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
2249000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-3569144
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-13176
Annuals > 0 > balance Sheet > cash
1038952
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
1038952
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
1145503
Annuals > 0 > balance Sheet > payables
83206
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
318284
Annuals > 0 > balance Sheet > equity
827219
Annuals > 0 > cash Flow > net Income
-3585965
Annuals > 0 > cash Flow > depreciation
29997
Annuals > 0 > cash Flow > change In Working Capital
3007
Annuals > 0 > cash Flow > cash From Operations
-3164536
Annuals > 0 > cash Flow > capital Expenditures
4
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
0
Annuals > 0 > cash Flow > net Change In Cash
-3164536
Annuals > 0 > ratios > PE
-1.5944708759448645
Annuals > 0 > ratios > PB
0.05981245595180962
Annuals > 0 > ratios > ROE
-433.49645015407043
Annuals > 0 > ratios > ROA
-313.0471941147252
Annuals > 0 > ratios > FCF
-3164540
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
33
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
5090236
Annuals > 1 > income Statement > operating Income
-5090236
Annuals > 1 > income Statement > interest Expense
16233
Annuals > 1 > income Statement > pretax Income
-5087029
Annuals > 1 > income Statement > net Income
-5087029
Annuals > 1 > income Statement > eps
-2.6552500785557025
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
1915838
Annuals > 1 > income Statement > income Tax Expense
-5090.24
Annuals > 1 > income Statement > EBITDA
-5070796
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
3207
Annuals > 1 > balance Sheet > cash
4203488
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
4230604
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
4308620
Annuals > 1 > balance Sheet > payables
156758
Annuals > 1 > balance Sheet > short Term Debt
313858
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
313858
Annuals > 1 > balance Sheet > equity
3994762
Annuals > 1 > cash Flow > net Income
-5087029
Annuals > 1 > cash Flow > depreciation
5090000
Annuals > 1 > cash Flow > change In Working Capital
20561
Annuals > 1 > cash Flow > cash From Operations
-4293265
Annuals > 1 > cash Flow > capital Expenditures
5
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
3143361
Annuals > 1 > cash Flow > net Change In Cash
-1149904
Annuals > 1 > ratios > PE
-2.6552500785557025
Annuals > 1 > ratios > PB
0.010550925436859567
Annuals > 1 > ratios > ROE
-127.34247997753059
Annuals > 1 > ratios > ROA
-118.06631821789809
Annuals > 1 > ratios > FCF
-4293270
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
6311481
Annuals > 2 > income Statement > operating Income
-6311481
Annuals > 2 > income Statement > interest Expense
8875
Annuals > 2 > income Statement > pretax Income
-6312535
Annuals > 2 > income Statement > net Income
-6312535
Annuals > 2 > income Statement > eps
-39.90173954817259
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
158202
Annuals > 2 > income Statement > income Tax Expense
-7821
Annuals > 2 > income Statement > EBITDA
-6303660
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-1054
Annuals > 2 > balance Sheet > cash
5353392
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
5560013
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
5560013
Annuals > 2 > balance Sheet > payables
229764
Annuals > 2 > balance Sheet > short Term Debt
394786
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
394786
Annuals > 2 > balance Sheet > equity
5165227
Annuals > 2 > cash Flow > net Income
-6312535
Annuals > 2 > cash Flow > depreciation
6311481
Annuals > 2 > cash Flow > change In Working Capital
154758
Annuals > 2 > cash Flow > cash From Operations
-4611737
Annuals > 2 > cash Flow > capital Expenditures
3
Annuals > 2 > cash Flow > cash From Investing
5141384
Annuals > 2 > cash Flow > cash From Financing
5141384
Annuals > 2 > cash Flow > net Change In Cash
529647
Annuals > 2 > ratios > PE
-39.90173954817259
Annuals > 2 > ratios > PB
0.0006738220798427638
Annuals > 2 > ratios > ROE
-122.21215059860873
Annuals > 2 > ratios > ROA
-113.53453669982427
Annuals > 2 > ratios > FCF
-4611740
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
6720445
Annuals > 3 > income Statement > operating Income
-6720445
Annuals > 3 > income Statement > interest Expense
7414
Annuals > 3 > income Statement > pretax Income
-6728396
Annuals > 3 > income Statement > net Income
-6728396
Annuals > 3 > income Statement > eps
-4.993677373100299
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
1347383
Annuals > 3 > income Statement > income Tax Expense
6788
Annuals > 3 > income Statement > EBITDA
-6720982
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-7951
Annuals > 3 > balance Sheet > cash
4823745
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
5093264
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
5093264
Annuals > 3 > balance Sheet > payables
225965
Annuals > 3 > balance Sheet > short Term Debt
302926
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
302926
Annuals > 3 > balance Sheet > equity
4790338
Annuals > 3 > cash Flow > net Income
-6728396
Annuals > 3 > cash Flow > depreciation
6720445
Annuals > 3 > cash Flow > change In Working Capital
-13441
Annuals > 3 > cash Flow > cash From Operations
-4142915
Annuals > 3 > cash Flow > capital Expenditures
5
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
3897394
Annuals > 3 > cash Flow > net Change In Cash
-245521
Annuals > 3 > ratios > PE
-4.993677373100299
Annuals > 3 > ratios > PB
0.006187961267033766
Annuals > 3 > ratios > ROE
-140.4576462036708
Annuals > 3 > ratios > ROA
-132.1038139786196
Annuals > 3 > ratios > FCF
-4142920
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.3290715979644137
Valuation > metrics > PB
0.027638287840978906
Valuation > final Score
70
Valuation > verdict
97.2% Undervalued
Profitability > metrics > ROE
-41.34079793105161
Profitability > metrics > ROA
-37.373685880424226
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.10614719841441424
Risk > metrics > Interest Coverage
-3941.693654266958
Risk > final Score
-15707
Risk > verdict
High
Liquidity > metrics > Current Ratio
23.033810936837643
Liquidity > metrics > Quick Ratio
23.033810936837643
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-1664
Prev Risks > 1
-842
Prev Risks > 2
-494
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:08:39.043Z
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAug Highlights: Will TPVG outperform during market rallies - Entry Point & AI Enhanced Trading Alerts baoquankhu1.vn
Read more →Is GYRO stock a top momentum play - 2025 Technical Overview & Weekly High Conviction Trade Ideas bollywoodhelpline.com
Read more →Showing 2 of 9
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Lixte Biotechnology Holdings Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.